Melatonin improves insulin resistance and hepatic steatosis by downregulating AHSG and reducing endoplasmic reticulum stress, highlighting the therapeutic potential of targeting fetuin-A in NAFLD (Heo et al., 2018). Here, AHSG is linked to metabolic dysfunction-associated steatotic liver disease.